DrugId:  1
1. Name:  Maltodextrin
2. Groups:  Investigational
3. Description:  Maltodextrin is under investigation for the treatment and prevention of Autism, Pouchitis, Inflammation, Colonic Cancer, and Atopic Dermatitis, among others. Maltodextrin has been investigated for the prevention and treatment of Fatigue, Thalassemia, Constipation, Type I Diabetes, and Sickle Cell Anemia, among others.
4. Indication:  Not Available
DrugId:  2
1. Name:  Lactulose
2. Groups:  Approved
3. Description:  A synthetic disaccharide used in the treatment of constipation and hepatic encephalopathy. It has also been used in the diagnosis of gastrointestinal disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p887)
4. Indication:  For the treatment of constipation and hepatic encephalopathy.
DrugId:  3
1. Name:  Technetium Tc-99m exametazime
2. Groups:  Approved
3. Description:  Technetium Tc-99m exametazime is a radiopharmaceutical sold under the trade name Ceretec, and is used by nuclear medicine physicians for the detection of altered regional cerebral perfusion in stroke and other cerebrovascular diseases. It can also be used for the labelling of leukocytes to localise intra-abdominal infections and inflammatory bowel disease. Exametazime, also known as hexamethylpropyleneamine oxime or HMPAO, acts as a chelating agent for the Tc-99m radioisotope.
4. Indication:  Technetium Tc99m exametazime scintigraphy (with or without methylene blue stabilization) may be useful as an adjunct in the detection of altered regional cerebral perfusion in stroke. Tc99m exametazime without methylene blue stabilization is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease.
DrugId:  4
1. Name:  Interleukin-10
2. Groups:  Investigational
3. Description:  Interleukin-10 has been used in trials studying the prevention and treatment of Vasculitis, Pancreatitis, Bile Duct Diseases, Pancreatic Diseases, and Gallbladder Diseases, among others.
4. Indication:  Not Available
DrugId:  5
1. Name:  Sulfasalazine
2. Groups:  Approved
3. Description:  A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
4. Indication:  For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.
DrugId:  6
1. Name:  Olsalazine
2. Groups:  Approved
3. Description:  Olsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. Olsalazine is a derivative of salicylic acid. Inactive by itself (it is a prodrug), it is converted by the bacteria in the colon to mesalamine. Mesalamine works as an anti-inflammatory agent in treating inflammatory diseases of the intestines.
4. Indication:  For the treatment of Inflammatory Bowel Disease and Ulcerative Colitis.
DrugId:  7
1. Name:  TU-100
2. Groups:  Investigational
3. Description:  TU-100 has been used in trials studying the treatment of Abdominal Pain, Colonic Transit, Crohn's Disease, Rectal Sensation, and Gastric Emptying, among others.
4. Indication:  Not Available
DrugId:  8
1. Name:  NVS antibody
2. Groups:  Investigational
3. Description:  This drug has been developed using Medarex's UltiMAb Human Antibody Development System to treat autoimmune diseases.
4. Indication:  Investigated for use/treatment in autoimmune diseases and rheumatoid arthritis.
DrugId:  9
1. Name:  Burlulipase
2. Groups:  Investigational
3. Description:  Burlulipase has been used in trials studying the treatment of Lung Diseases, Cystic Fibrosis, Pancreatic Insufficiency, Digestive System Diseases, and Respiratory Tract Diseases.
4. Indication:  Not Available
DrugId:  10
1. Name:  Picosulfuric acid
2. Groups:  Approved
3. Description:  Picosulfuric acid (as sodium picosulfate) is a contact laxative used as a treatment for constipation or to prepare the large bowel before colonoscopy or surgery.
4. Indication:  For cleansing of the colon as a preparation for colonoscopy in adults.
DrugId:  11
1. Name:  Bisacodyl
2. Groups:  Approved
3. Description:  Bisacodyl is an organic compound that is used as a stimulant laxative drug. It works directly on the colon to produce a bowel movement. It is typically prescribed for relief of constipation and for the management of neurogenic bowel dysfunction as well as part of bowel preparation before medical examinations, such as for a colonoscopy.
4. Indication:  Indicated for cleansing of the colon as a preparation for colonoscopy in adults. 
DrugId:  12
1. Name:  AV608
2. Groups:  Investigational
3. Description:  AV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).
4. Indication:  Investigated for use/treatment in anxiety disorders, irritable bowel syndrome (IBS), and urinary incontinence.
DrugId:  13
1. Name:  TRX1
2. Groups:  Investigational
3. Description:  TRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells. TRX1 is being developed for the potential treatment of autoimmune diseases in collaboration with Genentech, Inc. TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom.
4. Indication:  Investigated for use/treatment in autoimmune diseases.
DrugId:  14
1. Name:  LX-2931
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in rheumatoid arthritis, inflammatory disorders (unspecified), and autoimmune diseases.
DrugId:  15
1. Name:  PN0621
2. Groups:  Investigational
3. Description:  PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. It is being developed by Peptech.
4. Indication:  Intended for the treatment of auto-immune diseases such as rheumatoid arthritis, psoriasis and Crohn's disease.
DrugId:  16
1. Name:  Lexaptepid Pegol
2. Groups:  Investigational
3. Description:  Lexaptepid Pegol has been used in trials studying the treatment of Anemia, Inflammation, Chronic Diseases, End Stage Renal Disease, and Anemia of Chronic Disease.
4. Indication:  Not Available
DrugId:  17
1. Name:  R1295
2. Groups:  Investigational
3. Description:  R1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis. Integrins are associated to the pathology seen in some of the autoimmune diseases such as rheumatoid arthritis. 
4. Indication:  Investigated for use/treatment in rheumatoid arthritis.
DrugId:  18
1. Name:  Polihexanide
2. Groups:  Approved, Investigational
3. Description:  Polihexanide has been used in trials studying the treatment, prevention, and supportive care of Caries, Neoplasm, Skin Diseases, Nail Diseases, and Dental Plaque, among others.
4. Indication:  Not Available
DrugId:  19
1. Name:  PDE4
2. Groups:  Investigational
3. Description:  Merck has developed a selective PDE4 inhibitor for the treatment of inflammatory diseases, such as asthma and chronic obstructive pulmonary disease. Whereas the potential therapeutic utility of PDE4 inhibition has been demonstrated in various preclinical animal models (e.g., in rheumatoid arthritis and multiple sclerosis), clinical evaluation has been restricted by dose-limiting side effects, mainly nausea and emesis.
4. Indication:  Investigated for use/treatment in asthma and chronic obstructive pulmonary disease (COPD).
DrugId:  20
1. Name:  Prucalopride
2. Groups:  Approved
3. Description:  Prucalopride (brand name Resolor, developed by Johnson & Johnson and licensed to Movetis) is a drug acting as a selective, high affinity 5-HT4 receptor agonist which targets the impaired motility associated with chronic constipation, thus normalising bowel movements. Prucalopride was approved for use in Europe in 2009 and in Canada (named Resotran) on December 7, 2011 but it has not been approved by the Food and Drug Administration for use in the United States. The drug has also been tested for the treatment of chronic intestinal pseudo-obstruction.
4. Indication:  Investigated for use/treatment in constipation, ileus, and pediatric indications.
DrugId:  21
1. Name:  AVI-4020
2. Groups:  Investigational
3. Description:  AVI-4020 is a neugene antisense drug candidate for the treatment of patients with acute West Nile virus disease who have serious neurological impairment (WNV neuroinvasive disease).
4. Indication:  Investigated for use/treatment in infectious and parasitic disease (unspecified) and viral infection.
DrugId:  22
1. Name:  Namilumab
2. Groups:  Investigational
3. Description:  Namilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.
4. Indication:  Not Available
DrugId:  23
1. Name:  ATL-2502
2. Groups:  Investigational
3. Description:  ATL-2502(Colal-Pred) is an old drug (prednisolone metasulphobenzoate, a steroid) with a new delivery system that releases the medication only in the colon. Releasing the drug directly into the colon reduces the potential for significant side effects often experienced with steroid drugs. Colal-Pred is being studied for use in ulcerative colitis.
4. Indication:  Investigated for use/treatment in inflammatory bowel disease and ulcerative colitis.
DrugId:  24
1. Name:  humanized SMART Anti-IL-12 Antibody
2. Groups:  Investigational
3. Description:  The humanized anti-IL-12 antibody is an important addition to PDL's already strong pipeline of humanized antibodies being developed for the treatment of autoimmune diseases. SMART Anti-IL-12 Antibody was humanized at PDL from a murine anti-IL-12 antibody that was licensed, together with certain intellectual property related to anti-IL-12 therapy, from Hoffmann-La Roche Inc. IL-12 is a cytokine that may have considerable potential as a target in the therapy of autoimmune diseases.
4. Indication:  Investigated for use/treatment in autoimmune diseases and inflammatory disorders (unspecified).
DrugId:  25
1. Name:  GW 597599
2. Groups:  Investigational
3. Description:  GW 597599, a neurokinin-1 (NK1) receptor antagonist is currently in phase II trials for chemotherapy-induced vomiting; functional dyspepsia; depression and anxiety.
4. Indication:  Investigated for use/treatment in adverse effects (chemotherapy), anxiety disorders, depression, and gastrointestinal diseases and disorders (miscellaneous).
